Elsa Sotiriadis
Biology is becoming a programmable technology, and most leadership teams still treat it as someone else’s R and D problem. The commercial consequences of that blind spot are accelerating across materials, health, food, energy and computing. Boards need a clear read on which of these shifts are hype, which are imminent, and what a credible corporate response looks like.
Dr Elsa Sotiriadis is a synthetic biologist, former deep tech venture capitalist and futurist who helps leadership teams read the commercial implications of digital biology and converging frontier technologies.
Full Profile
Why organisations work with Dr Elsa Sotiriadis
- She speaks about digital biology from inside the field, with a working PhD in synthetic biology from Imperial College London and the University of Hong Kong, not as a commentator translating other people’s research.
- Her early-stage VC years at SOSV, where she helped build 25 deep tech and biotech start-ups, give her a founder-level view of which frontier-science claims hold up when money and product cycles are attached.
- She frames biotech alongside AI, computation and materials, which matches how corporate strategy teams actually have to evaluate these shifts rather than through isolated technology silos.
- Her science-fiction work, including the Writers of the Future honourable-mention novella Replicon, gives her a distinct capability for painting concrete, specific future scenarios rather than generic trend talks.
- She is comfortable with board-level audiences and Fortune 500 innovation teams, and has advised on innovation strategy across sustainability, energy and digital biology.
Biography highlights
- International PhD in synthetic biology, Imperial College London and the University of Hong Kong.
- Master of Research in Synthetic and Systems Biology, Imperial College London.
- Former early-stage venture capitalist at SOSV, where she helped build 25 deep tech start-ups.
- PhD research on programmable DNA aptamers as anti-cancer agents, recognised with awards including from MIT and the Swiss Academy of Sciences.
- Contributor to Singularity Hub; featured by Silicon Republic among 15 women to follow in biotech.
- Science-fiction author (pen name Elsa Solaris / EA Solaris); debut novella Replicon received an honourable mention at the Writers of the Future competition.
- TEDx speaker on digital biology at TEDx University of Nicosia.
Biography
Digital biology is quietly turning life itself into a design space. DNA can now be read, written and programmed; cells can be engineered to produce materials, medicines and food; and computation is folding biology into a development stack that looks increasingly like software. For most boards, this is still an unfamiliar language.
Dr Elsa Sotiriadis works at the centre of that language. Her international PhD in synthetic biology, taken jointly at Imperial College London and the University of Hong Kong, focused on programmable DNA aptamers as anti-cancer agents, a line of research recognised by MIT and the Swiss Academy of Sciences. She then moved from the lab into venture capital at SOSV, one of the most active early-stage deep tech investors, where she helped build 25 start-ups across biotech and frontier science.
That combination shapes how she speaks. She is not a generalist trend-spotter. She can read a scientific claim, weigh it against a business model, and tell a corporate audience what is worth taking seriously in the next five to ten years. She has advised governments and Fortune 500 companies on innovation strategy across sustainability, energy and digital biology, and reaches wider audiences through Singularity Hub, TEDx and her science fiction, written under the pen name Elsa Solaris. Her debut novella Replicon received an honourable mention at the Writers of the Future competition.
Senior teams bring her in when the questions get specific. Where is synthetic biology likely to hit our supply chain. What does it mean for our R and D portfolio when biology starts to behave like software. Which parts of the convergence story between AI, biotech and materials should our strategy actually plan for.
Key speaking topics
- Digital biology and synthetic biology
- Frontier and deep technology convergence
- Biotech and healthcare innovation
- Climate, materials and industrial biotech
- Strategic foresight and long-range scenario thinking
- Deep tech venture building and start-up ecosystems
Ideal for
- Board and executive strategy sessions evaluating exposure to biotech and frontier-science shifts.
- R and D, innovation and venture leaders in pharma, materials, food, chemicals and energy.
- Chief Strategy Officers and Chief Scientific Officers shaping long-range technology bets.
- Corporate foresight and futures teams working on scenarios beyond the next planning cycle.
Audience outcomes
- A working mental model of what “digital biology” actually means and where it is already commercial.
- A clearer view of which biotech, AI and deep tech claims are credible versus speculative on current evidence.
- Specific examples of deep tech start-ups reshaping health, materials, food and energy.
- Concrete scenarios of how biology-as-technology could reshape their own sector in the next decade.
- A sharper question set to take back into their own strategy and R and D conversations.
Talks
This talk maps the convergence of biology and technology from lab-grown meat to 3D-printed tissue to show business leaders what the bio-revolution means for their industries and how to position for it now.
Key takeaways:
- The bio-revolution is the successor to the computer chip revolution: a shift already reshaping nutrition, materials, and healthcare at scale
- Concrete examples from science and industry show how today’s science fiction, algae batteries, bioreactor-grown textiles, smart health devices is becoming mainstream infrastructure
- A practical lens for expanding organisational thinking about what is possible, and what action to take before the wave arrives
Drawing on data, global case studies, and a projected energy landscape of 2050, this talk gives business leaders the strategic and practical tools to move from climate commitments to credible climate action.
Key takeaways:
- A clear-eyed view of where the sustainability landscape is heading including the energy transition, circularity, and resource efficiency, and what it demands from businesses operating today
- Sector-specific examples of how global industries are adapting, from joint ventures to new business models, making the strategic options concrete rather than abstract
- A versatile toolkit for delivering measurable climate impact, from data-driven operational improvements to bold moves in emerging technology
This talk demonstrates how AI, extended reality, blockchain, and big data are converging to reshape the working world, and equips leaders with a framework for adopting these technologies faster and more effectively than their competitors.
Key takeaways:
- A grounded, evidence-based picture of how the workplace is being restructured by emerging technologies, from augmented reality platforms to haptic interfaces and smart devices
- An honest answer to the question of what AI does and does not replace, and why the leaders who understand that distinction will move faster
- Practical guidance on how organisations can accelerate adoption of new technologies without waiting for the field to stabilise